ICRM
LGND icon

Insight Capital Research & Management’s Ligand Pharmaceuticals LGND Stock Holding History

Insight Capital Research & Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3,709
Closed -$120K – 159
2013
Q3 		$120K Buy
+3,709
New +$104K 0.03% 161

Other funds holding LGND

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Insight Capital Research & Management's LGND Position: Q4 2013 in Review

Insight Capital Research & Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2013, closing a stake of 3,709 shares — an estimated $120K sold.

Insight Capital Research & Management first reported a position in LGND in Q3 2013 and held it in 1 quarter. The position peaked at $120K in Q3 2013. 165 funds tracked by Wall St. Rank hold LGND as of Q4 2013.

  • Insight Capital Research & Management reported no remaining Ligand Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Insight Capital Research & Management sold 3,709 Ligand Pharmaceuticals shares in Q4 2013, an estimated $120K.
  • Insight Capital Research & Management first reported a position in Ligand Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Insight Capital Research & Management's Ligand Pharmaceuticals position peaked at $120K in Q3 2013.
  • 165 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2013.

Based on Insight Capital Research & Management's 13F filing for Q4 2013, filed 12 Feb 2014.